YIR-819 TFA salt

CAS No. 1883372-87-9

YIR-819 TFA salt( YIR819 )

Catalog No. M12923 CAS No. 1883372-87-9

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    YIR-819 TFA salt
  • Note
    Research use only, not for human use.
  • Brief Description
    YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).
  • Description
    YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM); A useful lead compound for the further development of HIV-1 entry inhibitors and could potentially be useful for co-administration with neutralizing antibodies for the treatment of HIV infection and AIDS.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    YIR819
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1883372-87-9
  • Formula Weight
    606.044
  • Molecular Formula
    C25H35ClF3N7O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N1-(4-chlorophenyl)-N2-(1-(2-(2-guanidinoacetamido)ethyl)-1-azaspiro[5.5]undecan-4-yl)oxalamide TFA salt

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6. 2. Boonstra A, et al. Antivir Ther. 2012;17(4):657-67.
molnova catalog
related products
  • HIV-1 Integrase Inhi...

    A novel compound that disrupts the HIV-1 integrase LEDGF interaction.

  • BMS-986001

    A thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-2 isolates from treatment-naive individuals with EC50 of 30-81 nM.

  • GSK-364735

    GSK-364735 is a human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitor with antiviral activity and is used in the study of retroviral infections.